Skip to main content
Erschienen in: Endocrine 3/2017

22.06.2017 | Editorial

Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer

verfasst von: Nicole M. Iñiguez-Ariza, Keith C. Bible

Erschienen in: Endocrine | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Excerpt

Small-molecule kinase inhibitors have emerged as effective therapies for patients suffering from progressive, metastatic, radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC) [1]. Sorafenib and lenvatinib are now subject to regulatory approval in the United States and European Union for this indication [2, 3], with other agents—including sunitinib, pazopanib, axitinib, vandetanib, and cabozantinib—also approved for other cancer indications and showing evidence of benefit in RAIR DTC based on phase 2 trial data [1]. These kinase inhibitors are thought to demonstrate efficacy principally through their actions on vascular endothelial growth factors (VEGFRs), but they also inhibit many other kinases. Moreover, these systemically administered therapeutics are expected to inhibit targets not only in tumor, but also in host tissues, with potential therefore for their efficacies to be affected not only by tumor-specific, but also by host-specific, alterations [1]. …
Literatur
1.
Zurück zum Zitat K.C. Bible, M. Ryder, Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat. Rev. Clin. Oncol. 13, 403–416 (2016)CrossRefPubMed K.C. Bible, M. Ryder, Evolving molecularly targeted therapies for advanced-stage thyroid cancers. Nat. Rev. Clin. Oncol. 13, 403–416 (2016)CrossRefPubMed
2.
Zurück zum Zitat M.S. Brose, C.M. Nutting, B. Jarzab et al., Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384, 319–328 (2014)CrossRefPubMedPubMedCentral M.S. Brose, C.M. Nutting, B. Jarzab et al., Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384, 319–328 (2014)CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat M. Schlumberger, M. Tahara, L.J. Wirth et al., Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621–630 (2015)CrossRef M. Schlumberger, M. Tahara, L.J. Wirth et al., Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N. Engl. J. Med. 372, 621–630 (2015)CrossRef
4.
Zurück zum Zitat V. Marotta, C. Sciammarella, M. Capasso, et al., Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. Endocrine doi:10.1007/s12020-016-1200-6 (2016) V. Marotta, C. Sciammarella, M. Capasso, et al., Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib. Endocrine doi:10.​1007/​s12020-016-1200-6 (2016)
5.
Zurück zum Zitat M. Tahara, M. Schlumberger, R. Elisei et al., Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur. J. Cancer 75, 213–221 (2017)CrossRefPubMed M. Tahara, M. Schlumberger, R. Elisei et al., Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur. J. Cancer 75, 213–221 (2017)CrossRefPubMed
Metadaten
Titel
Toward predictive biomarkers of response to kinase inhibitor therapies in differentiated thyroid cancer
verfasst von
Nicole M. Iñiguez-Ariza
Keith C. Bible
Publikationsdatum
22.06.2017
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 3/2017
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-017-1342-1

Weitere Artikel der Ausgabe 3/2017

Endocrine 3/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.